(Q35026009)

5 August 2017

1 reference

title

Monoclonal antibodies as therapeutics in oncology (English)

1 reference

5 August 2017

Mohit Trikha

1

1 reference

PubMed ID

12482522

5 August 2017

Li Yan

series ordinal

2

1 reference

PubMed ID

12482522

5 August 2017

Marian T Nakada

series ordinal

3

1 reference

5 August 2017

1 December 2002

1 reference

Current Opinion in Biotechnology

5 August 2017

1 reference

5 August 2017

13

1 reference

5 August 2017

6

1 reference

5 August 2017

609-614

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Improving the efficacy of antibody-based cancer therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Rituximab: ongoing and future clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Trastuzumab: hopes and realities

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Mylotarg: antibody-targeted chemotherapy comes of age.

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Alemtuzumab: a novel monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

A review of modifications to recombinant antibodies: attempt to increase efficacy in oncology applications

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

The EGFR as a target for anticancer therapy--focus on cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Cardiac dysfunction in the trastuzumab clinical trials experience

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Receptor tyrosine kinases as targets for anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Monoclonal antibody strategies to block angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

From angiogenesis to lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Putting tumours in context

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Molecular profiling of tissue samples using laser capture microdissection

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Clinical proteomics: personalized molecular medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Towards proteome-wide production of monoclonal antibody by phage display

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

1 reference

7 January 2021

Antibody-cytokine fusion proteins for the therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0958-1669%2802%2900348-8

7 January 2021

10.1016/S0958-1669(02)00348-8

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12482522